摘要
慢性肾脏病(CKD)是临床常见的疾病,肾性贫血是CKD最常见的并发症之一,也是影响CKD患者预后的重要危险因素。关于肾性贫血的治疗一直都是全球关注的焦点。本文简要阐述CKD患者肾性贫血治疗的目标值及研究进展。
Renoprival anemia is the most common complication of chronic kidney disease(CKD),and is also an important risk factor affecting the prognosis of CKD patients.The treatment of renoprival anemia has been the hotspot in clinical research.This review describes the drug therapy of renoprival anemia in CKD patients.
出处
《世界临床药物》
CAS
2016年第4期228-231,共4页
World Clinical Drug
基金
福建省卫生厅医学创新课题(项目编号:2012-CXB-35)
关键词
慢性肾脏病
肾性贫血
药物治疗
chronic kidney disease
renoprival anemia
drug therapy
